Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for hypereosinophilic syndrome (HES) – randomized double-blind placebo-controlled phase III trial in China
CTR20242248Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in hypereosinophilic syndrome (HES), sponsored by AstraZeneca. Started Sep 2024; status: active.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on CTR20242248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242248.